Halozyme Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
423
- Stock Symbol
-
HALO
- Investments
-
4
- Share Price
-
$91.35
- (As of Friday Closing)
Halozyme Therapeutics General Information
Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Contact Information
Website
www.halozyme.comCorporate Office
- 12390 El Camino Real
- San Diego, CA 92130
- United States
Corporate Office
- 12390 El Camino Real
- San Diego, CA 92130
- United States
Halozyme Therapeutics Stock Performance
As of 20-Nov-2026, Halozyme Therapeutics’s stock price is $91.35. Its current market cap is $10.4B with 114M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $91.35 | $92.99 | $61.23 - $134.00 | $10.4B | 114M | 2.26M | $4.19 |
Halozyme Therapeutics Financials Summary
As of 30-Sep-2026, Halozyme Therapeutics has a trailing 12-month revenue of $1.8B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 14,445,830 | 8,723,072 | 6,920,571 | 5,896,685 |
| Revenue | 1,802,448 | 1,396,611 | 1,015,324 | 829,253 |
| EBITDA | 805,642 | 496,401 | 585,527 | 378,191 |
| Net Income | 485,420 | 316,889 | 444,091 | 281,594 |
| Total Assets | 3,473,346 | 2,525,323 | 2,063,477 | 1,733,270 |
| Total Debt | 3,250,303 | 2,142,630 | 1,505,798 | 1,499,248 |
Halozyme Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Halozyme Therapeutics Comparisons
Industry
Financing
Details
Halozyme Therapeutics Competitors (28)
One of Halozyme Therapeutics’s 28 competitors is Heron Therapeutics, a Formerly VC-backed company based in Cary, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Heron Therapeutics | Formerly VC-backed | Cary, NC | ||||
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Halozyme Therapeutics Patents
Halozyme Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-246488-S | Injection device | Active | 12-Jun-2025 | ||
| WO-2026222046-A1 | Off-body priming device | Pending | 16-Apr-2025 | ||
| WO-2026187389-A1 | Combination therapy with antibody-drug conjugates and hyaluronidases | Pending | 05-Mar-2025 | ||
| WO-2026165589-A1 | Subcutaneous delivery of lipid nanoparticle formulations | Pending | 03-Feb-2025 | ||
| WO-2026143138-A1 | Prefilled autoinfusion device | Pending | 23-Dec-2024 | A61M5/20 |
Halozyme Therapeutics Signals
Halozyme Therapeutics Acquisitions (4)
Halozyme Therapeutics’s most recent deal was a Merger/Acquisition with Halozyme Surf Bio for . The deal was made on 22-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Halozyme Surf Bio | 22-Dec-2025 | Merger/Acquisition | Drug Delivery | ||
| Elektrofi | 18-Nov-2025 | Merger/Acquisition | Drug Delivery | ||
| Antares Pharma | 24-May-2022 | Merger/Acquisition | Drug Delivery | ||
| Global Yacht Services | 11-Mar-2004 | Merger/Acquisition | Marine |
Halozyme Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.11 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Halozyme Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Halozyme Surf Bio | Palo Alto, CA | 2021 | |
| Elektrofi | Boston, MA | 2016 |
Halozyme Therapeutics FAQs
-
When was Halozyme Therapeutics founded?
Halozyme Therapeutics was founded in 1998.
-
Where is Halozyme Therapeutics headquartered?
Halozyme Therapeutics is headquartered in San Diego, CA.
-
What is the size of Halozyme Therapeutics?
Halozyme Therapeutics has 423 total employees.
-
What industry is Halozyme Therapeutics in?
Halozyme Therapeutics’s primary industry is Biotechnology.
-
Is Halozyme Therapeutics a private or public company?
Halozyme Therapeutics is a Public company.
-
What is Halozyme Therapeutics’s stock symbol?
The ticker symbol for Halozyme Therapeutics is HALO.
-
What is the current stock price of Halozyme Therapeutics?
As of 20-Nov-2026 the stock price of Halozyme Therapeutics is $91.35.
-
What is the current market cap of Halozyme Therapeutics?
The current market capitalization of Halozyme Therapeutics is $10.4B.
-
What is Halozyme Therapeutics’s current revenue?
The trailing twelve month revenue for Halozyme Therapeutics is $1.8B.
-
Who are Halozyme Therapeutics’s competitors?
Heron Therapeutics, Immune-Onc Therapeutics, Ayala Pharmaceuticals, Xenetic Biosciences, and Mission Therapeutics are some of the 28 competitors of Halozyme Therapeutics.
-
What is Halozyme Therapeutics’s annual earnings per share (EPS)?
Halozyme Therapeutics’s EPS for 12 months was $4.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process